Mersin University   Report issue

Academic/Hospital Phase 3 Phase 4
Founded: Mersin Turkey (1992)

Organization Overview

First Clinical Trial
2016
NCT02795416
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

ahmet.karaman@mersin.edu.tr | Hilal Altundal | Mersin City Hospital | Mersin City Research and Application Hospital | Mersin City Research & Training Hospital | Mersin Training and Research Hospital | Mersin University | Mersin University Faculty of Nursing | Mersin University, Faculty of Nursing, Ciftlikkoy Campus, 33343, Yenisehir, Mersin | Mersin University Medical Faculty | Mersin University Medical School | Mersin University Nursing Faculty | Mersin University, Nursing Faculty | Mersin University Scholl of Medicine | Near East University Faculty of Medicine, Lefkosa-10 TRNC, Mersin, Turkey | Turkey, Mersin University, Mersin, Yenişehir, Turkey, 33343 | Zühal Artuvan

Active Ingredients

Drugs in Phase 4 Trials (2)

bupivacaine (Exparel) (1 trial)

norepinephrine (levophed) (1 trial)

Drugs in Phase 3 Trials (1)

secukinumab (cosentyx) (1 trial)

Drugs in Other Trials (6)

caraway seed (1 trial)

coffee (1 trial)

dextrose (1 trial)

lavender (1 trial)

lidocaine (xylocaine) (1 trial)

naproxen (naprosyn) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Psoriasis (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 9